These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1260 related items for PubMed ID: 17356050

  • 1. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A, Patton L, De Iasio R, Palladoro F, Pagotto U, Pasquali R.
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
    [Abstract] [Full Text] [Related]

  • 2. Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A, Patton L, Prontera O, Fanelli F, Ciampaglia W, Cognigni GE, Pagotto U, Pasquali R.
    J Endocrinol Invest; 2011 Oct; 34(9):685-91. PubMed ID: 21586896
    [Abstract] [Full Text] [Related]

  • 3. Insulin-like factor 3 -- a new hormone related to polycystic ovary syndrome?
    Szydlarska D, Grzesiuk W, Trybuch A, Kondracka A, Kowalik I, Bar-Andziak E.
    Endokrynol Pol; 2012 Oct; 63(5):356-61. PubMed ID: 23115068
    [Abstract] [Full Text] [Related]

  • 4. Parallel variations of insulin-like peptide 3 (INSL3) and antimüllerian hormone (AMH) in women with the polycystic ovary syndrome according to menstrual cycle pattern.
    Pelusi C, Fanelli F, Pariali M, Zanotti L, Gambineri A, Pasquali R.
    J Clin Endocrinol Metab; 2013 Oct; 98(10):E1575-82. PubMed ID: 23928669
    [Abstract] [Full Text] [Related]

  • 5. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R, Patton L, Pocognoli P, Cognigni GE, Gambineri A.
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [Abstract] [Full Text] [Related]

  • 6. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ, Laughlin GA, Bützow T, Maheshwari H, Baumann G, Yen SS.
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [Abstract] [Full Text] [Related]

  • 7. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
    Thierry van Dessel HJ, Lee PD, Faessen G, Fauser BC, Giudice LC.
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
    [Abstract] [Full Text] [Related]

  • 8. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM.
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the correlation between insulin like factor 3, polycystic ovary syndrome, and ovarian maldescent.
    Seyam E, Hefzy E.
    Gynecol Endocrinol; 2018 Jun; 34(6):481-488. PubMed ID: 29254383
    [Abstract] [Full Text] [Related]

  • 10. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 11. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS.
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [Abstract] [Full Text] [Related]

  • 12. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
    Adams JM, Taylor AE, Crowley WF, Hall JE.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031
    [Abstract] [Full Text] [Related]

  • 13. Follicle luteinization in hyperandrogenic follicles of polycystic ovary syndrome patients undergoing gonadotropin therapy for in vitro fertilization.
    Foong SC, Abbott DH, Zschunke MA, Lesnick TG, Phy JL, Dumesic DA.
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2327-33. PubMed ID: 16551732
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome.
    Leblanc S, Battista MC, Noll C, Hallberg A, Gallo-Payet N, Carpentier AC, Vine DF, Baillargeon JP.
    Endocrinology; 2014 Sep; 155(9):3684-93. PubMed ID: 24971613
    [Abstract] [Full Text] [Related]

  • 15. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels.
    Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D.
    Am J Physiol Endocrinol Metab; 2009 Feb; 296(2):E238-43. PubMed ID: 18957615
    [Abstract] [Full Text] [Related]

  • 16. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC, Rizos D, Valsamakis G, Deligeoroglou E, Grigoriou O, Chrousos GP, Creatsas G, Mastorakos G.
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [Abstract] [Full Text] [Related]

  • 17. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
    Barber TM, Wass JA, McCarthy MI, Franks S.
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
    [Abstract] [Full Text] [Related]

  • 18. Steroid metabolome profiling of follicular fluid in normo- and hyperandrogenic women with polycystic ovary syndrome.
    Yang Z, Zhou W, Zhou C, Zhou Y, Liu X, Ding G, Hu Y, Pan J, Sheng J, Jin L, Huang H.
    J Steroid Biochem Mol Biol; 2021 Feb; 206():105806. PubMed ID: 33340681
    [Abstract] [Full Text] [Related]

  • 19. Plasma selenium levels in Turkish women with polycystic ovary syndrome.
    Coskun A, Arikan T, Kilinc M, Arikan DC, Ekerbiçer HÇ.
    Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):183-6. PubMed ID: 23490536
    [Abstract] [Full Text] [Related]

  • 20. [The effects of hyperinsulinmia and insulin-like growth factor-1 on hyperandrogenism in polycystic ovarian syndrome].
    Liang X, Zhuang G, Fan Q.
    Zhonghua Yi Xue Za Zhi; 1997 Apr; 77(4):266-9. PubMed ID: 9596926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.